These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 36898378)

  • 1. The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients.
    Friedrich MJ; Neri P; Kehl N; Michel J; Steiger S; Kilian M; Leblay N; Maity R; Sankowski R; Lee H; Barakat E; Ahn S; Weinhold N; Rippe K; Bunse L; Platten M; Goldschmidt H; Müller-Tidow C; Raab MS; Bahlis NJ
    Cancer Cell; 2023 Apr; 41(4):711-725.e6. PubMed ID: 36898378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of resistance to bispecific T-cell engagers in multiple myeloma and their clinical implications.
    Letouzé E; Moreau P; Munshi N; Samur M; Minvielle S; Touzeau C
    Blood Adv; 2024 Jun; 8(11):2952-2959. PubMed ID: 38513088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific T-cell engagers for treatment of multiple myeloma.
    Ravi G; Costa LJ
    Am J Hematol; 2023 Mar; 98 Suppl 2():S13-S21. PubMed ID: 35702871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dawn of a new era of antibody-drug conjugates and bispecific T-cell engagers for treatment of multiple myeloma: a systematic review of literature.
    Khattak ZE; Hashmi H; Khan SI; Aamir S; Arif U; Khan AI; Darwin A; Singh AD; Khouri J; Anwer F
    Ann Hematol; 2021 Sep; 100(9):2155-2172. PubMed ID: 34318356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities.
    Baeuerle PA; Wesche H
    Curr Opin Oncol; 2022 Sep; 34(5):552-558. PubMed ID: 35880455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leveraging a physiologically-based quantitative translational modeling platform for designing B cell maturation antigen-targeting bispecific T cell engagers for treatment of multiple myeloma.
    Yoneyama T; Kim MS; Piatkov K; Wang H; Zhu AZX
    PLoS Comput Biol; 2022 Jul; 18(7):e1009715. PubMed ID: 35839267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current use of bispecific antibodies to treat multiple myeloma.
    Lee H; Neri P; Bahlis NJ
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):332-339. PubMed ID: 38066842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma.
    Davis JA; Shockley A; Hashmi H
    J Oncol Pharm Pract; 2022 Jun; 28(4):960-968. PubMed ID: 35006032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T Cell Receptor-Directed Bispecific T Cell Engager Targeting MHC-Linked NY-ESO-1 for Tumor Immunotherapy.
    Li Y; Zhao W; Shen Y; Xu Y; Chen S; Pan L
    Biomedicines; 2024 Apr; 12(4):. PubMed ID: 38672132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T cell engager immunotherapy.
    Lee KJ; Choi D; Tae N; Song HW; Kang YW; Lee M; Moon D; Oh Y; Park S; Kim JH; Jeong S; Yang J; Park U; Hong DH; Byun MS; Park SH; Sohn J; Park Y; Im SK; Choi SS; Kim DH; Lee SW
    Cell Rep Med; 2024 May; 5(5):101567. PubMed ID: 38744277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells.
    DiLillo DJ; Olson K; Mohrs K; Meagher TC; Bray K; Sineshchekova O; Startz T; Kuhnert J; Retter MW; Godin S; Sharma P; Delfino F; Lin J; Smith E; Thurston G; Kirshner JR
    Blood Adv; 2021 Mar; 5(5):1291-1304. PubMed ID: 33651100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of T-cell engagers selective for cells co-expressing two antigens.
    Dicara DM; Bhakta S; Go MA; Ziai J; Firestein R; Forrest B; Gu C; Leong SR; Lee G; Yu SF; Polson AG; Agard NJ
    MAbs; 2022; 14(1):2115213. PubMed ID: 36206404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment.
    Seckinger A; Delgado JA; Moser S; Moreno L; Neuber B; Grab A; Lipp S; Merino J; Prosper F; Emde M; Delon C; Latzko M; Gianotti R; Lüoend R; Murr R; Hosse RJ; Harnisch LJ; Bacac M; Fauti T; Klein C; Zabaleta A; Hillengass J; Cavalcanti-Adam EA; Ho AD; Hundemer M; San Miguel JF; Strein K; Umaña P; Hose D; Paiva B; Vu MD
    Cancer Cell; 2017 Mar; 31(3):396-410. PubMed ID: 28262554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How I treat triple-class refractory multiple myeloma.
    Costa LJ; Hungria V; Mohty M; Mateos MV
    Br J Haematol; 2022 Jul; 198(2):244-256. PubMed ID: 35373352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-Cell Engagers-The Structure and Functional Principle and Application in Hematological Malignancies.
    Cech P; Skórka K; Dziki L; Giannopoulos K
    Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IBI379, a novel B cell maturation antigen/CD3 bispecific T-cell engager, displays high antitumor efficacy in preclinical models of multiple myeloma.
    Fei K; Ni H; Zhu M; Kuang Z; Wu M; Wu Z; Wang F; Zhou S; Jing H; Wu W; Wu D; Bai D; Chen B
    Cancer Lett; 2022 Jun; 536():215663. PubMed ID: 35381307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager.
    Xiao X; Cheng Y; Zheng X; Fang Y; Zhang Y; Sun R; Tian Z; Sun H
    Front Immunol; 2023; 14():1113303. PubMed ID: 37114050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An anti-B cell maturation antigen bispecific antibody for multiple myeloma.
    Ramadoss NS; Schulman AD; Choi SH; Rodgers DT; Kazane SA; Kim CH; Lawson BR; Young TS
    J Am Chem Soc; 2015 Apr; 137(16):5288-91. PubMed ID: 25826669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.